

MYRIAD GENETICS INC  
Form 8-K  
May 02, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 2, 2006

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**0-26642**  
(Commission  
File Number)

**87-0494517**  
(IRS Employer  
Identification No.)

**320 Wakara Way**

**Salt Lake City, Utah 84108**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: MYRIAD GENETICS INC - Form 8-K

- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

Page 1 of 4 pages

**ITEM 2.02 Results of Operations and Financial Condition**

On May 2, 2006, Myriad Genetics, Inc. announced its financial results for the three and nine months ended March 31, 2006. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**ITEM 8.01 Other Events**

On May 2, 2006, Myriad Genetics, Inc. announced that it has initiated a Phase I human clinical trial of MPC-0920, its product candidate designed to be an orally available, direct thrombin inhibitor. The trial will enroll healthy volunteers in a single, escalating dose format. The Phase I is designed to determine the safety, dose range and pharmacokinetics of the drug candidate. The information in the press release dated May 2, 2006 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.2 hereto.

**ITEM 9.01 Financial Statements and Exhibits.**

(d)

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Earnings release dated May 2, 2006 for the three and nine months ended March 31, 2006.
99.2	The Registrant's press release dated May 2, 2006 concerning MPC-0920.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: May 2, 2006

By: /s/ Peter D. Meldrum  
Peter D. Meldrum  
President and Chief Executive Officer

Page 3 of 4 pages

EXHIBIT INDEX

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Earnings release dated May 2, 2006 for the three and nine months ended March 31, 2006.
99.2	The Registrant's press release dated May 2, 2006 concerning MPC-0920.

Page 4 of 4 pages